Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India

Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) said its joint venture CoSara Diagnostics was invited to the 2nd Advanced TB Diagnostics Course in Chennai, India, held Dec 15–19, 2025 at ICMR–NIRT.

The multi-day workshop, hosted with McGill International TB Centre and global partners, brings national TB programs, diagnostics developers, industry and experts from WHO, Gates Foundation, FIND and academic institutions to review the diagnostics value chain, new technologies, cost-effectiveness modeling, policy development and strategies to close the TB case-finding gap across the South‑East Asian Region.

News Market Reaction – CODX

+5.31%

8 alerts

+5.31% Session close to close

+3.6% Peak Tracked

-11.6% Trough Tracked

$18.26M Market Cap

1.0x Rel. Volume

In the Dec 18 session, CODX gained 5.31%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.6% during that session. Argus tracked a trough of -11.6% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.3% in the session following this news. A strong positive reaction aligns with COD...

Analysis

The stock moved +5.3% in the session following this news. A strong positive reaction aligns with CODX’s pattern of sizable moves on JV and platform news, as seen in prior events with moves up to 13.37%. Participation in a regional TB diagnostics course reinforces CoSara’s positioning in India-focused tuberculosis testing. However, past divergence on seemingly positive TB and conference updates suggests that enthusiasm has not always been durable, so investors have historically reassessed these spikes against broader fundamentals.

Key Figures

Workshop dates: December 15-19, 2025 Program length: Five-day program Course edition: 2nd Advanced TB Diagnostics Course

3 metrics

Workshop dates December 15-19, 2025 2nd Advanced TB Diagnostics Course in Chennai, India

Program length Five-day program Advanced TB diagnostics and implementation workshop

Course edition 2nd Advanced TB Diagnostics Course Regional capacity-building workshop for SEAR countries

Historical Context

5 past events · Latest: Dec 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 17	Influenza assay update	Positive	+6.5%	In silico analysis confirmed Logix Smart ABC coverage of H3N2 mutation.
Dec 09	Platform AI presentation	Positive	+4.5%	Conference presentation on portable Co-Dx PCR platform and AI integration.
Dec 08	CoSara virology meeting	Positive	-7.4%	CoSara VIROCON presence and Phase I/II MTB and HPV preclinical data.
Nov 20	TB conference address	Positive	-5.8%	Address on MTB test adoption and potential India/South Africa rollout.
Nov 18	Respiratory trial start	Positive	+13.4%	Initiation of clinical evaluations for upper respiratory multiplex POC test.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

News tied to platform progress or JV activity often triggers sizable moves in both directions, with a slight tilt toward positive alignment on more recent technical or platform updates.

Recent Company History

Over the past month, CODX has issued multiple updates on its Co-Dx PCR platform and tuberculosis/respiratory testing pipeline. Events on Nov 18 and Nov 20 highlighted clinical evaluations and MTB test planning, while Dec 8 and Dec 17 detailed CoSara’s role and influenza assay performance. Today’s TB diagnostics workshop participation further reinforces the company’s focus on TB and point-of-care expansion, particularly via its Indian joint venture.

Key Terms

tuberculosis, diagnostics value chain, cost-effectiveness modeling, evidence-based policy

4 terms

tuberculosis medical

"address emerging needs in tuberculosis detection, research, and implementation"

A contagious bacterial infection that most often attacks the lungs and can range from a mild, slow-developing illness to a severe, long-lasting disease. It matters to investors because its prevalence, treatment options, diagnostic tests and public health policies drive demand for medicines, vaccines and medical services; like a smoldering fire, outbreaks and progress in therapies can quickly change market size, regulatory priorities and company valuations.

diagnostics value chain technical

"The workshop includes sessions covering the full diagnostics value chain, highlights"

The diagnostics value chain is the series of steps that take a medical test from idea to use: research and development, regulatory approval, manufacturing, distribution, laboratory or point‑of‑care testing, and reporting of results. Think of it like an assembly line that not only builds a product but also delivers and explains it to the customer. Investors care because strengths or bottlenecks at any step affect costs, speed to market, revenue predictability and regulatory risk, all of which shape returns.

cost-effectiveness modeling technical

"highlights new technologies in the innovation pipeline, examines cost-effectiveness modeling"

A quantitative way to compare the costs and health benefits of medical treatments or technologies to see which gives the most value for money. Think of it like comparing two cars by both price and fuel efficiency: investors use these models to predict whether a product will be adopted, reimbursed by insurers or governments, and able to earn returns based on projected uptake and pricing.

evidence-based policy technical

"cost-effectiveness modeling and evidence-based policy development, and explores"

A decision-making approach that uses reliable data, research and measurable outcomes to design and evaluate policies so actions are based on what has been shown to work rather than opinion or tradition. For investors, evidence-based policy matters because it tends to make regulatory and spending decisions more predictable and transparent, reducing surprise risks and helping assess how government choices may affect sectors, company profits and long-term market trends.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, Dec. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that its joint venture, CoSara Diagnostics Pvt. Ltd. ("CoSara"), has been invited to participate in the 2nd Advanced TB Diagnostics Course, a capacity-building workshop for countries in the South-East Asian Region (SEAR). The event will take place December 15-19, 2025 at the ICMR–National Institute for Research in Tuberculosis (NIRT) located in Chennai, India. 

Hosted by ICMR-NIRT in partnership with the McGill International TB Centre and other global health organizations, the multi-day workshop brings together leading experts, national TB programs, diagnostics developers and industry partners to address emerging needs in tuberculosis detection, research, and implementation. The workshop includes sessions covering the full diagnostics value chain, highlights new technologies in the innovation pipeline, examines cost-effectiveness modeling and evidence-based policy development, and explores practical strategies to close the TB case-finding gap across SEAR nations.

The five-day program will also feature presentations and panel discussions led by national and international faculty, including experts from WHO, The Gates Foundation, FIND, Boston University, and India's central TB institutions. Industry innovators will additionally present technology pitches highlighting emerging diagnostic solutions.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) to identify genetic markers for use in applications other than infectious disease.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-joint-venture-cosara-invited-to-participate-in-2nd-advanced-tb-diagnostics-course-in-chennai-india-302645600.html

SOURCE Co-Diagnostics

FAQ

What is CoSara Diagnostics' role at the 2nd Advanced TB Diagnostics Course in Chennai Dec 15–19, 2025?

CoSara Diagnostics was invited to participate among industry partners to present and engage in sessions across the diagnostics value chain.

How does Co-Diagnostics (CODX) benefit from CoSara's participation in the Chennai TB diagnostics workshop?

Participation increases CoSara's visibility with national TB programs and global health organizations, supporting networking and technology exposure.

Which organizations and experts will present at the Dec 15–19, 2025 TB diagnostics course in Chennai?

Presenters include WHO, Gates Foundation, FIND, McGill International TB Centre, Boston University and India's central TB institutions.

What topics will the 2nd Advanced TB Diagnostics Course in Chennai cover for CODX/CoSara?

The workshop covers the diagnostics value chain, new technologies, cost-effectiveness modeling, evidence-based policy, and case-finding strategies.

Will CoSara present a technology pitch or product at the Chennai workshop?

The workshop program includes industry technology pitches, and CoSara was invited to participate among industry innovators.